Page 1 of 5Free preview · 1–5

About this document

Regional clinical guidance for managing vitamin D deficiency and insufficiency in adults in Cornwall and IoS. Covers risk factors, supplementation advice, indications for testing, interpretation of vitamin D levels, and treatment with colecalciferol and calcium preparations. Includes loading and maintenance regimens, monitoring considerations, and guidance for malabsorption, renal disease and drug-induced deficiency. Developed and approved via CAPC in March 2018, with review scheduled for March 2021.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

Note that OptimiseRx may prompt other products be considered for prescribing apart from those named in this document. CORNWALL & IoS GUIDELINE FOR THE MANAGEMENT OF VITAMIN D DEFICIENCY& INSUFFICIENCY IN ADULTS INTRODUCTION Vitamin D is essential for skeletal growth and bone health. Dietary sources in the UK are very limited and oily fish is the only significant source. Small amounts are provided by egg yolk, red meat and fortified foods, such as some breakfast cereals and fat spreads (margarine). In addition, infant formula milk has to be fortified with vitamin D (this is voluntary for formula milks for toddlers). Breast milk contains very little vitamin D and is not a significant source. The major natural source is from skin synthesis following exposure to sunlight. In a fair skinned person, 20-30 minutes of sunlight exposure to the face and forearms at midday generates about 2000 units of vitamin D. Two or 3 sunlight exposures per week are sufficient to achieve adequate vitamin D levels in the summer if individuals have adequate levels to begin with. However, those with low vitamin D levels, pigmented skin and the elderly need increased exposure time or frequency to get the same level of vitamin D synthesis. Sun exposure should be avoided if someone has a history of skin cancer, or conditions such as xeroderma pigmentosum or actinic keratosis. From mid-October to the beginning of April in the UK there is no ambient ultraviolet sunlight of the appropriate wavelength. During this time, the population relies on both body stores from sun exposure in the summer and dietary sources to maintain vitamin D levels. The recommended oral daily intake of vitamin D for an adult in the UK is around 400IU (10mcg). The average adult daily diet in the UK provides only 3.7mcg of vitamin D for men and 2.8mcg for women. Food sources which contain greater than 5mcg per portion of vitamin D include 70g sardines, 100g tinned salmon, pilchards or tuna, 110g of cooked mackerel or herring and 130g cooked kipper. Consumption of food sources alone, in the absence of skin synthesis, will not provide optimal vitamin D status. Vitamin D deficiency develops when there is inadequate exposure to sunlight or a lack of vitamin D in the diet and usually takes a long time to develop as there is slow release of the vitamin from body stores to cover times of deficiency. Factors predisposing to Vitamin D deficiency:  Inadequate UV light exposure - Northern latitude, air pollution, habitual sunscreen use, dark or pigmented skin, institutionalised/ housebound/ reduced mobility i.e. wheelchair dependency, clothing which limits sunlight exposure or avoidance of sunlight  Poor dietary intake/ malabsorbtion - Poor diet, malabsorbtion including short bowel, cholestatic jaundice, Crohn’s Disease, cystic fibrosis, coeliac disease, cholestyramine use  Metabolic risk - Reduced synthesis (eg over 65years old), pregnant and breastfeeding women particularly teenagers and young women, multiple short interval pregnancies, infants who are exclusively breast fed, obesity, increased breakdown eg drugs (rifampicin, anticonvulsants particularly phenytoin or carbamazepine treatment, highly active antiretroviral treatment, glucocorticoids), reduced stores: liver disease Definition of Vitamin D Deficiency Low vitamin D status (sometimes called vitamin D deficiency) is defined by the Department of Health as a plasma concentration of 25 hydroxyvitamin D (the main circulating form of the vitamin) of below 25 nmol/litre (equal to10 ng/ml). Several risk groups were identified in the CMO guidance1 (2012) which recommended vitamin D supplementation of 400 units (10mcg) daily to those groups of the population at risk of vitamin D deficiency. 1 https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213703/dh_132508.pdf

Page 2

Note that OptimiseRx may prompt other products be considered for prescribing apart from those named in this document. This advice has been superseded by Public Health England (PHE) 2016 guidance2 which advises people should consider taking a daily supplement containing 10 mcg of vitamin D in autumn and winter, and people whose skin has little or no exposure to the sun, like those in institutions such as care homes, or who always cover their skin when outside, risk vitamin D deficiency and need to take a supplement throughout the year. In these groups, supplementation is suggested without measurement of 25-OHD. For these groups described above, the advice is to take an appropriate over the counter low strength preparation of approximately 400 units which can be bought at low cost from any pharmacy or health food shop. NB: multi-vitamin preparations and fish liver oils are not suitable for the treatment of vitamin D deficiency as this may lead to vitamin A toxicity. https://www.eclipsesolutions.org/UploadedFiles/318_KCCG_Vitamin-D-in-adults-information- leaflet.pdf PHE has also made recommendations for infants and children aged under 5 years. The National Osteoporosis Society (NOS) have published a practical clinical guideline to support health professionals with an aim to provide a uniform approach in the management of adult patients with vitamin D deficiency.3 The guideline provides clarity on who should be tested for vitamin D deficiency, how the results should be interpreted and how deficiency should be treated. It is important to highlight that this clinical guideline intends to inform patient management but not to influence public health policy. WHEN TO MEASURE VITAMIN D LEVELS Consider measuring vitamin D  In patients presenting with persistent musculoskeletal weakness, myalgia & arthralgia  Hypocalcaemia  Management of Primary Hyperparathyroidism  Unexplained osteoporosis/ osteoporosis refractory to treatment  Malabsorption syndromes Please note: Requests by GPs for vitamin D testing require a clear indication / rationale for the test. Re-testing after treatment is not currently considered necessary. When measuring vitamin D levels, concurrent illness and seasonal factors should be considered. Recent illness or operations may cause a falsely low reading. Interpretation of vitamin D levels A lack of national standards on whom to provide with additional vitamin D, when to test and how to treat led to variations in guidance across the country. Recent advice from NOS provides more consistency and makes recommendations on when testing is justified. In agreement with the Institute of Medicine (IOM)4, they propose that the following vitamin D thresholds are adopted by UK practitioners in respect to bone health; 2 https://www.gov.uk/government/news/phe-publishes-new-advice-on-vitamin-d 3 The National Osteoporosis Society. Vitamin D and bone health: A practical clinical guideline for patient management. April 2013. 4 IOM (Institute of Medicine). Dietary Reference Intakes for Calcium and Vitamin D. A. Catharine Ross, Christine L. Taylor, Ann L. Yaktine, and Heather B. Del Valle [Editors]. 2011.

Page 3

Note that OptimiseRx may prompt other products be considered for prescribing apart from those named in this document. >50 nmol/L of 25−OHD unlikely to require intervention 30–50 nmol/L of 25−OHD may be inadequate in some people < 30 nmol/L of 25−OHD deficiency requiring treatment in adult patients MANAGEMENT - Vitamin D Inadequacy (25-OHD 30-50nmol/l) Treatment is advised in patients with the following:  fragility fracture, documented osteoporosis or high fracture risk  treatment with antiresorptive medication for bone disease  symptoms suggestive of vitamin D deficiency  increased risk of developing vitamin D deficiency in the future because of reduced exposure to sunlight, religious/cultural dress code, dark skin, etc. – it is this group of patients who are recommended to take a prophylactic over the counter dose of 400 units  raised PTH  medication with antiepileptic drugs or oral glucocorticoids  conditions associated with malabsorption. Where vitamin D alone is required, there is no need for the high dose regime and 800-1,600 units of colecalciferol daily is adequate. It may take up to 3 months to replenish stores. Routine monitoring is not required for vitamin D doses ≤2000 units daily. Clinicians should use the cheapest preparation available after consideration of clinical indications and potential risks. Stexerol D3 tablet 25mcg vitamin D3 (1000 units colecalciferol) Lower cost product Licensed UK product Colecalciferol is derived from healthy live sheep’s wool fat – may be acceptable to vegetarians Fultium D3 capsule 20mcg vitamin D3 (800 units colecalciferol) Higher cost product Licensed UK product Contains glycerol and gelatin. The gelatin used in the capsule shell is certified to Halal standards Desunin tablet 20mcg vitamin D3 (800 units colecalciferol) Higher cost product Licensed UK product Does not contain gelatin, peanut oil or soya. Colecalciferol is derived from healthy live sheep’s wool fat – may be acceptable to vegetarians For bone health, calcium and vitamin D3 800 units/day is appropriate. Locally agreed products are as below, though RCHT may not stock the complete range listed. Calceos chewable tablet calcium 500mg and 10 mcg vitamin D3 (400 units) Licensed UK product One tablet twice a day Calfovit D3 powder in sachet Calcium 1.2g and 20 mcg vitamin D3 (800 units) Licensed UK product One sachet daily Adcal D3 chewable tablet calcium 600mg and 10 mcg vitamin D3 (400 units) Licensed UK product One tablet twice a day Calcichew D3 caplet calcium 500mg and 10 mcg vitamin D3 (400 units) Licensed UK product One tablet twice a day

Page 4

Note that OptimiseRx may prompt other products be considered for prescribing apart from those named in this document. MANAGEMENT - Vitamin D deficiency (25-OHD <30nmol/L) For patients with symptoms of deficiency the recommended treatment is based on fixed loading doses of vitamin D (up to a total of about 300,000 units) given either as weekly or daily split doses, followed by lifelong maintenance treatment of about 800 units a day. Higher doses of up to 2000 units a day, occasionally up to 4000 units a day, may be used for certain groups of people, for example those with malabsorption disorders. Several treatment regimens are available, including 50,000 units once a week for 6 weeks (300,000 units in total), 20,000 units twice a week for 7 weeks (280,000 units in total), or 4000 units daily for 10 weeks (280,000units in total). Locally agreed products are as follows: Fultium D3 capsule 500 mcg vitamin D3 (20,000 units colecalciferol) Licensed UK product Contains glycerol and gelatin. The gelatin used in the capsule shell is certified to Halal standards InVita D3 oral solution 625 mcg vitamin D3 (25,000 units colecalciferol) per 1ml unit amp oral solution Licensed UK product Colecalciferol is derived from healthy live sheep’s wool fat – may be acceptable to vegetarians Maintenance therapy can begin immediately after the completion of the high dose phase. It is recommended to check calcium and phosphate 4 weeks following the initiation of the high dose phase in case primary hyperparathyroidism has been unmasked. Routine repeat of vitamin D levels is not needed if symptoms of vitamin D deficiency resolve. If symptoms do not resolve despite adequate vitamin D repletion then the symptoms are not due to vitamin D deficiency. Patients with high or high-normal calcium levels and vitamin D deficiency may have coexistent primary hyperparathyroidism. Consider referral to a specialist clinic with an interest in calcium eg Endocrine. Patients with significant hypomagnesaemia (Mg2+ <0.5mmol/l) from any cause may develop significant hypocalcaemia due to ineffective release of PTH. PTH measurement is not recommended in patients with severe hypomagnesaemia as it may be uninterpretable. Replacement with combination magnesium and activated vitamin D may be necessary - seek specialist help. Alfacalcidol or calcitriol should NOT be used for routine treatment of vitamin D deficiency as they carry a higher risk of toxicity and require close monitoring. Malabsorption syndromes Oral therapy is more effective than IM injections except in cases of significant malabsorption. Options include:  High dose oral therapy e.g. 20,000 units - 25,000 units oral colecalciferol weekly  IM injection of ergocalciferol. Initially 300,000 units IM injections 3 months apart followed by maintenance treatment of 300,000 units IM 6 monthly (a licensed product). If the injection is used, close monitoring of serum and urinary calcium, phosphate and renal function is needed to avoid hypercalcaemia. Renal disease Patients on haemodialysis at RCH have their vitamin D levels reviewed and replaced as necessary as part of their dialysis care, and therefore will be excluded from this guideline.

Page 5

Note that OptimiseRx may prompt other products be considered for prescribing apart from those named in this document. Drug induced vitamin D deficiency If the patient is taking drugs that accelerate Vitamin D metabolism or if there are concerns regarding absorption, then, higher doses may be required. The Medicines and Healthcare Regulatory Agency have advised that patients on long-term anticonvulsant therapy require vitamin D supplementation 400 units daily as a prophylaxis. Guidance developed & approved via CAPC March 2018. For review March 2021

Tags

Doxxly editorial guide

Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults: summary, contents and background

This guide helps you understand the scope of Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults is a 5-page documentcredited to Juno Y. Merrick. Regional clinical guidance for managing vitamin D deficiency and insufficiency in adults in Cornwall and IoS. Covers risk factors, supplementation advice, indications for testing, interpretation of vitamin D levels, and treatment with colecalciferol and calcium preparations. Includes loading and maintenance regimens, monitoring considerations, and guidance for malabsorption, renal disease and drug-induced deficiency. Developed and approved via CAPC in March 2018, with review scheduled for March 2021. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of Vitamin D deficiency, Vitamin D insufficiency, Adult clinical guidance, Bone health, Colecalciferol, Vitamin D testing, Cornwall & IoS with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with Vitamin D deficiency, Vitamin D insufficiency, Adult clinical guidance, Bone health, Colecalciferol, Vitamin D testing, Cornwall & IoS. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 5 pages in the player.

  1. Part 1

    Vitamin D deficiency

    Use this section of the reading guide to identify how Vitamin D deficiency appears in Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults, note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    Vitamin D insufficiency

    Use this section of the reading guide to identify how Vitamin D insufficiency appears in Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults, note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    Adult clinical guidance

    Use this section of the reading guide to identify how Adult clinical guidance appears in Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults, note important terms, and connect the subject to the wider purpose of the work.

  4. Part 4

    Bone health

    Use this section of the reading guide to identify how Bone health appears in Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults, note important terms, and connect the subject to the wider purpose of the work.

  5. Part 5

    Colecalciferol

    Use this section of the reading guide to identify how Colecalciferol appears in Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults, note important terms, and connect the subject to the wider purpose of the work.

  6. Part 6

    Vitamin D testing

    Use this section of the reading guide to identify how Vitamin D testing appears in Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults, note important terms, and connect the subject to the wider purpose of the work.

  7. Part 7

    Cornwall & IoS

    Use this section of the reading guide to identify how Cornwall & IoS appears in Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults, note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Juno Y. Merrick

Doxxly credits Juno Y. Merrick as the author or creator of Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is eclipsesolutions.org. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit eclipsesolutions.org

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Explore more Medicine & Wellbeing resources

Frequently asked questions about Cornwall & IoS Guideline for the Management of Vitamin D Deficiency & Insufficiency in Adults

Practical answers about reading, downloading and understanding this document on Doxxly.

More in Medicine & Wellbeing